Figure 2.

Flowchart illustrating the workflow of the RHOBTB2 case using mediKanren. (A) Based on the conclusions of the case analysis, the analyst used mediKanren to identify therapeutic strategies that will regulate RHOBTB2 gene expression. Ten concepts were returned by mediKanren using the SemMedDB KG that were predicted to regulate RHOBTB2 expression, but none of the concepts were drugs or compounds. Therefore, a two-hop approach was taken with E2F1, a gene that was identified as a regulator of RHOBTB2. (B) A second query was run to look for downregulators of E2F1, which resulted in 212 concepts. After filtering for drugs, sorting by relevance, and manually reviewing for FDA-approved compounds that pass the blood-brain barrier, Celecoxib was identified. RHOBTB2, Rho Related BTB Domain Containing 2; CURIE, compact uniform resource identifier; UMLS, Unified Medical Language System; E2F1, E2F Transcription Factor 1.